{
    "root": "dac2462e-31fb-4725-9f75-2ebdde41ab96",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "KIMMTRAK",
    "value": "20250506",
    "ingredients": [
        {
            "name": "TEBENTAFUSP",
            "code": "N658GY6L3E"
        }
    ],
    "indications": "KIMMTRAK is indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma.",
    "contraindications": "Recommended dosage: 20 mcg intravenously on Day 1, 30 mcg intravenously on Day 8, 68 mcg intravenously on Day 15, and 68 mcg intravenously once every week thereafter ( 2.2 ). Dilute and administer by intravenous infusion over 15-20 minutes ( 2.2 , 2.4 ). See Full Prescribing Information for instructions on preparation and administration of the diluted solution for intravenous infusion ( 2.2 , 2.4 ). Dosage interruption or permanent discontinuation may be required based on individual safety and tolerability ( 2.3 ).",
    "warningsAndPrecautions": "How Supplied\n                  \n                  Each KIMMTRAK (tebentafusp-tebn) injection carton (NDC 80446-401-01) contains:\n                  \n                     One single-dose vial containing 100 mcg of tebentafusp-tebn in 0.5 mL of sterile, preservative-free, clear, colorless or slightly yellowish solution.\n                  \n                  The vial stopper is not made with natural rubber latex.\n                  \n                     Storage and Handling\n                  \n                  \n                     Store KIMMTRAK vials in the original carton refrigerated at 2째C to 8째C (36째F to 46째F) and protect from light until time of use. Do not freeze. Do not shake.",
    "adverseReactions": "None."
}